XML 138 R26.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
SEGMENT REPORTING

NOTE 17 – SEGMENT REPORTING

 

A. Basis for segmentation

 

The Group operates through various operating segments, which include the wholesale sector, the pharmaceutical manufacturing sector, the nutraceuticals and pharmaceuticals sector and other, with only the first three of them being reportable segments based on the criteria (quantitative thresholds) of ASC 280. The financial information utilized by our Chief Operating Decision Maker (“CODM”), which is our CEO, for resource allocation and performance evaluation is included within the operating segments described above. The reconciling items presented in the tables below are excluded from the segment data provided to the Chief Operating Decision Maker (“CODM”). The “Other” category primarily consists of corporate expenses incurred by the Group’s parent entity, including, but not limited to, costs related to SEC legal and compliance matters, executive compensation, audit and review fees, and other corporate overhead expenses.

 

B. Information about reportable segments

 

The table below presents information about the Company's reportable segments for the three-month period ended March 31, 2025. The accounting policies followed in the preparation of the reportable segments are the same with those followed in the preparation of the Company's condensed consolidated financial statements.

 

Three-month period ended March 31, 2025

 

 

 

Wholesale

 

 

Pharma

manufacturing

 

 

Nutraceuticals & Pharmaceuticals

 

 

Other

 

 

Total

 

Revenues                                        

 

 

12,504,562

 

 

 

268,557

 

 

 

939,409

 

 

 

-

 

 

 

13,712,528

 

Cost of Sales

 

 

(11,320,936 )

 

 

(70,975 )

 

 

(270,818 )

 

 

-

 

 

 

(11,662,729 )

Gross Profit

 

 

1,183,626

 

 

 

197,582

 

 

 

668,591

 

 

 

-

 

 

 

2,049,799

 

General and Administrative expenses

 

 

(162,269 )

 

 

(155,454 )

 

 

(243,227 )

 

 

(361,140 )

 

 

(922,090 )

Salaries

 

 

(378,595 )

 

 

(363,670 )

 

 

(297,499 )

 

 

(255 )

 

 

(1,040,019 )

Sales and Marketing expenses

 

 

(715 )

 

 

(428 )

 

 

(27,012 )

 

 

0 )

 

 

(28,155 )

Research and Development costs

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(15,629 )

 

 

(15,629 )

Net finance costs

 

 

(149,274 )

 

 

-

 

 

 

53,493

 

 

 

-

 

 

 

(95,781 )

Segment profit / (loss)

 

 

492,773

 

 

 

(321,970 )

 

 

154,346

 

 

 

(377,024 )

 

 

(51,875 )

Reconciling items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

(52,880 )

 

 

(131,974 )

 

 

(99,807 )

 

 

(35,778 )

 

 

(320,439 )

Stock based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(556,613 )

 

 

(556,613 )

Foreign currency adjustments

 

 

59,428

 

 

 

-

 

 

 

109,943

 

 

 

6,454

 

 

 

175,825

 

Other income and expenses

 

 

27,556

 

 

 

12,341

 

 

 

88,701

 

 

 

(193,593 )

 

 

(64,995 )

Net profit/(loss) before Income Taxes

 

 

526,877

 

 

 

(441,603 )

 

 

253,184

 

 

 

(1,156,555 )

 

 

(818,097 )

 

The following summary describes the operations of each reportable segment:

 

Reportable segments

 

Operations

Wholesale

 

Distribution and export of pharmaceutical products

Pharma manufacturing

 

Production of pharmaceutical products

Nutraceutical and pharmaceuticals

 

Trade of owned nutraceutical & pharmaceutical products

NOTE 19 – SEGMENT REPORTING

 

A. Basis for segmentation

 

The Group operates through various operating segments, which include the wholesale sector, the pharmaceutical manufacturing sector, the nutraceuticals and pharmaceuticals sector and other, with only the first three of them being reportable segments based on the criteria (quantitative thresholds) of ASC 280. The financial information utilized by our Chief Operating Decision Maker (“CODM”), which is our CEO, for resource allocation and performance evaluation is included within the operating segments described above. The reconciling items presented in the tables below are excluded from the segment data provided to the Chief Operating Decision Maker (“CODM”). The “Other” category primarily consists of corporate expenses incurred by the Group’s parent entity, including, but not limited to, costs related to SEC legal and compliance matters, executive compensation, audit and review fees, and other corporate overhead expenses.

B. Information about reportable segments

 

The table below present's information about the Company's reportable segments for the 12-month period ended December 31, 2024. The accounting policies followed in the preparation of the reportable segments are the same with those followed in the preparation of the Company's consolidated financial statements.

 

Year ended December 31, 2024

 

 

 

Wholesale

 

 

Pharma

manufacturing

 

 

Nutraceuticals & Pharmaceuticals

 

 

Other

 

 

Total

 

Revenues                                        

 

 

51,593,787

 

 

 

865,373

 

 

 

1,967,242

 

 

 

-

 

 

 

54,426,402

 

Cost of Sales

 

 

(48,887,569 )

 

 

(249,061 )

 

 

(978,449 )

 

 

-

 

 

 

(50,115,079 )

General and Administrative expenses

 

 

(647,225 )

 

 

(773,429 )

 

 

(1,442,102 )

 

 

(4,176,049 )

 

 

(7,038,805 )

Salaries

 

 

(1,701,552 )

 

 

(1,243,568 )

 

 

(1,430,736 )

 

 

(1,317,580 )

 

 

(5,693,436 )

Sales and Marketing expenses

 

 

(10,516 )

 

 

(489 )

 

 

(255,559 )

 

 

(88,405 )

 

 

(354,969 )

Research and Development costs

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(533,293 )

 

 

(533,293 )

Net finance costs

 

 

(840,456 )

 

 

-

 

 

 

234,856

 

 

 

(265 )

 

 

(605,865 )

Segment profit / (loss)

 

 

(493,531 )

 

 

(1,401,174 )

 

 

(1,904,748 )

 

 

(6,115,592 )

 

 

(9,915,045 )

Reconciling items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

(231,344 )

 

 

(565,371 )

 

 

(334,075 )

 

 

(118,448 )

 

 

(1,249,238 )

Provisions

 

 

(1,021,818 )

 

 

(123,503 )

 

 

(3,549,111 )

 

 

-

 

 

 

(4,694,432 )

Impairment Charges

 

 

-

 

 

 

-

 

 

 

(160,948 )

 

 

(131,032 )

 

 

(291,980 )

Other income and expenses

 

 

(304,495 )

 

 

5,789

 

 

 

225,665

 

 

 

40,718

 

 

 

(32,323 )

Net profit/(loss) before Income Taxes

 

 

(2,051,188 )

 

 

(2,084,259 )

 

 

(5,723,217 )

 

 

(6,324,354 )

 

 

(16,183,018 )

 

The following summary describes the operations of each reportable segment:

 

Reportable segments

 

Operations

Wholesale

 

Distribution and export of pharmaceutical products

Pharma manufacturing

 

Production of pharmaceutical products

Nutraceutical and pharmaceuticals

 

Trade of owned nutraceutical & pharmaceutical products